Problem:
Reply with a thoughtful and substantive response that furthers the discussion. Possible posts could include asking a probing question, adding information to what they provided, or countering a statement with a different opinion or interpretation. All posts must be respectful, use appropriate language, and relevant to the topic. Prostate-specific antigen was initially used to assess the progression of patients diagnosed with prostate cancer. The prostate produces PSA in patients with or without prostate cancer. The level of PSA is assessed with blood draws and is thought to be elevated higher than usual in patients with prostate cancer. (National Cancer Institute, 2022). When analyzing the data given on the effectiveness of testing PSA and prostate cancer diagnosis, I am not confident that this would be beneficial to patients. The sensitivity of the patients with the disease that are correctly identified ranges from 80%-89% based on their ages, or 80-89% of patients with prostate cancer are true positives. Although these numbers seem slightly low, they are within an acceptable range. However, the specificity is noted to be much lower. The specificity of the patients who do not have prostate cancer that is correctly identified ranges between 27-40%%, meaning that 27-40% of patients